1. Home
  2. IZM vs MBIO Comparison

IZM vs MBIO Comparison

Compare IZM & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICZOOM Group Inc.

IZM

ICZOOM Group Inc.

HOLD

Current Price

$0.39

Market Cap

5.0M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.60

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZM
MBIO
Founded
2011
2015
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.3M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
IZM
MBIO
Price
$0.39
$0.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
138.3K
34.2K
Earning Date
10-24-2025
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.53
52 Week High
$2.74
$7.00

Technical Indicators

Market Signals
Indicator
IZM
MBIO
Relative Strength Index (RSI) 44.98 25.57
Support Level $0.35 $0.53
Resistance Level $0.99 $0.80
Average True Range (ATR) 0.04 0.03
MACD 0.01 -0.01
Stochastic Oscillator 56.74 2.74

Price Performance

Historical Comparison
IZM
MBIO

About IZM ICZOOM Group Inc.

ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: